Skip to main content
    T

    Thermo Fisher Scientific Inc (TMO)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $673.20
    +10.16 (+1.53%)

    Market Cap: $248.91B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    97%(38/39)
    Avg Surprise
    +6.06%
    Streak
    12 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$6.40
    Range$6.33 - $6.47
    21 analysts
    EPS Revisions
    1
    0
    7d
    1
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$6.37+0.6%
    60d ago$6.41-0.0%
    30d ago$6.41-0.1%
    7d ago$6.41-0.1%
    Current$6.40
    Revenue Consensus
    $12.0B
    Range$11.8B - $12.1B
    19 analysts
    Period ending Dec 31, 2026
    EPS Consensus$7.78
    Range$7.62 - $8.04
    26 analysts
    Revenue Consensus
    $13.4B
    Range$13.2B - $13.7B
    25 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$7.78---
    Sep 26EST
    		-$6.40---
    Jun 26
    Reported Jul 23
    		$6.03$5.71+5.60%Beat+12.5%
    Mar 26
    Reported Apr 23
    		$5.44$5.24+3.82%Beat+5.6%
    Dec 25
    Reported Jan 29
    		$6.57$6.45+1.86%Beat+7.7%
    Sep 25
    Reported Oct 22
    		$5.79$5.50+5.27%Beat+9.7%
    Jun 25
    Reported Jul 23
    		$5.36$5.23+2.49%Beat-0.2%
    Mar 25
    Reported Apr 23
    		$5.15$5.10+0.98%Beat+0.8%
    Dec 24
    Reported Jan 30
    		$6.10$5.94+2.69%Beat+7.6%
    Sep 24
    Reported Oct 23
    		$5.28$5.25+0.57%Beat-7.2%
    Jun 24
    Reported Jul 24
    		$5.37$5.12+4.88%Beat+4.3%
    Mar 24
    Reported Apr 24
    		$5.11$4.71+8.49%Beat+1.6%
    Dec 23
    Reported Jan 31
    		$5.67$5.64+0.53%Beat+5.0%
    Sep 23
    Reported Oct 25
    		$5.69$5.61+1.43%Beat+12.0%
    Jun 23
    Reported Jul 26
    		$5.15$5.43-5.16%Miss-6.5%
    Mar 23
    Reported Apr 26
    		$5.03$5.03+0.00%Beat-30.6%
    Dec 22
    Reported Feb 1
    		$5.40$5.20+3.85%Beat-17.4%
    Sep 22
    Reported Oct 26
    		$5.08$4.82+5.39%Beat-11.8%
    Jun 22
    Reported Jul 28
    		$5.51$4.98+10.64%Beat-1.6%
    Mar 22
    Reported Apr 28
    		$7.25$6.21+16.75%Beat+0.6%
    Dec 21
    Reported Feb 2
    		$6.54$5.27+24.10%Beat-7.8%
    Sep 21
    Reported Oct 27
    		$5.76$4.70+22.55%Beat+2.3%
    Jun 21
    Reported Jul 28
    		$5.60$5.47+2.38%Beat+44.0%
    Mar 21
    Reported Apr 29
    		$7.21$6.68+7.93%Beat+145.2%
    Dec 20
    Reported Feb 1
    		$7.09$6.57+7.91%Beat+99.7%
    Sep 20
    Reported Oct 21
    		$5.63$4.30+30.93%Beat+91.5%
    Jun 20
    Reported Jul 22
    		$3.89$2.89+34.60%Beat+28.0%
    Mar 20
    Reported Apr 22
    		$2.94$2.82+4.26%Beat+4.6%
    Dec 19
    Reported Jan 30
    		$3.55$3.54+0.28%Beat+9.2%
    Sep 19
    Reported Oct 23
    		$2.94$2.89+1.73%Beat+12.2%
    Jun 19
    Reported Jul 24
    		$3.04$3.00+1.33%Beat+10.5%
    Mar 19
    Reported Apr 24
    		$2.81$2.74+2.55%Beat+12.4%
    Dec 18
    Reported Jan 30
    		$3.25$3.18+2.20%Beat+16.5%
    Sep 18
    Reported Oct 24
    		$2.62$2.56+2.34%Beat+13.4%
    Jun 18
    Reported Jul 25
    		$2.75$2.63+4.56%Beat+19.6%
    Mar 18
    Reported Apr 25
    		$2.50$2.41+3.73%Beat+20.2%
    Dec 17
    Reported Jan 31
    		$2.79$2.67+4.49%Beat+15.8%
    Sep 17
    Reported Oct 25
    		$2.31$2.25+2.67%Beat-
    Jun 17
    Reported Jul 26
    		$2.30$2.27+1.32%Beat-
    Mar 17
    Reported Apr 26
    		$2.08$2.02+2.97%Beat-
    Dec 16
    Reported Jan 31
    		$2.41$2.38+1.26%Beat-

    Dividends

    Dividend Metrics

    Forward Yield0.28%
    Forward Annual Dividend$1.88
    Payout Ratio7.57%
    FrequencyQuarterly
    Pay MonthsJan, Apr, Jul, Oct

    Growth

    3Y CAGR+12.75%
    5Y CAGR+14.34%
    TMO dividend history and ex-dividend datesRun TMO in the free DRIP calculator

    Key Metrics

    Valuation
    P/E Ratio28.25EV/EBITDA26.01x
    Price/FCF34.13xFCF Yield2.93%
    Profitability
    Profit Margin15.00%Operating Margin18.80%
    ROE13.50%ROIC7.88%
    Financial Health
    Debt/Equity0.81xInterest Coverage5.45x
    Current Ratio1.55xQuick Ratio1.18x
    Trading Statistics
    Beta0.88Avg Volume2.40M
    52-Week High$694.3352-Week Low$434.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$661.12
    SMA 20$664.51
    SMA 50$631.87
    SMA 200$545.66
    EMA 10$663.32
    EMA 20$657.44
    EMA 50$629.21
    EMA 200$558.82

    MACD

    Line: 10.16Signal: 12.50Hist: -2.34

    ADX

    ADX: 37.8+DI: 29.5-DI: 13.2

    Aroon & PSAR

    Aroon Up76.0
    Aroon Down4.0
    PSAR$689.74

    Bollinger Bands

    Upper Band$684.29
    Lower Band$644.73
    %B Position595%(Upper)
    Band Width0.72

    RSI (14-Day)

    Neutral
    60.3

    Momentum Oscillators

    Stoch %K52.3
    Stoch %D44.5
    Williams %R-35.8
    ROC (10d)-0.3%
    Momentum-1.85
    CCI (20d)70.0
    MFI (14d)63.4

    Volatility Measures

    ATR (14d)$18.03(2.7%)
    StdDev (20d)9.89
    Hist Vol25.2%(Moderate)

    Volume Flow

    VWAP$671.23
    OBV43.3M
    AD Line-58.2M
    CMF (20d)0.190

    Volume Metrics

    Avg Vol (20d)2.3M
    Vol Ratio1.1x
    VWMA (20d)$663.40

    Pivot Points

    R3$678.35
    R2$672.37
    R1$667.70
    Pivot Point$661.72
    S1$657.05
    S2$651.07
    S3$646.40

    Advanced Oscillators

    TSI17.75
    Ultimate Osc53.5
    KST63.40

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$11.99B$11.01B$12.21B$11.12B$10.86B$10.36B$11.39B$10.60B$10.54B$10.35B$10.89B$10.57B
    Cost of Revenue$7.11B$6.58B$7.20B$6.54B$6.45B$6.13B$6.57B$6.27B$6.19B$6.14B$6.49B$6.26B
    Gross Profit$4.88B$4.43B$5.01B$4.58B$4.41B$4.24B$4.82B$4.33B$4.35B$4.21B$4.39B$4.32B
    Operating Expenses$2.79B$2.57B$2.76B$2.64B$2.57B$2.52B$2.81B$2.49B$2.53B$2.54B$2.54B$2.45B
    R&D$364.00M$336.00M$357.00M$346.00M$352.00M$342.00M$374.00M$346.00M$339.00M$331.00M$327.00M$319.00M
    SG&A$2.33B$2.18B$2.35B$2.16B$2.14B$2.08B$2.20B$2.10B$2.11B$2.18B$2.13B$2.05B
    Operating Income$2.09B$1.86B$2.25B$1.94B$1.83B$1.72B$2.02B$1.84B$1.82B$1.66B$1.85B$1.86B
    Interest Income$0$233.00M$259.00M$234.00M$0$203.00M$227.00M$277.00M$295.00M$279.00M$309.00M$246.00M
    Interest Expense$0$354.00M$365.00M$347.00M$0$303.00M$317.00M$356.00M$354.00M$363.00M$390.00M$359.00M
    Income Before Tax$1.92B$1.73B$2.15B$1.83B$1.71B$1.62B$1.94B$1.74B$1.76B$1.59B$1.74B$1.76B
    Income Tax Expense$167.00M$70.00M$153.00M$207.00M$92.00M$95.00M$149.00M$99.00M$128.00M$281.00M$133.00M$53.00M
    Net Income$1.74B$1.66B$1.97B$1.62B$1.62B$1.51B$1.82B$1.63B$1.55B$1.33B$1.61B$1.70B
    EBITDA$2.90B$2.59B$2.99B$2.60B$2.52B$2.42B$2.77B$2.56B$2.62B$2.51B$2.66B$2.73B
    EBIT$2.09B$1.85B$2.26B$1.94B$1.83B$1.72B$2.03B$1.82B$1.82B$1.67B$1.82B$1.88B
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    The Diversification Test Every Investor Should Run (Built Into GNG)

    Counting holdings is misleading - a 12-stock, 10-industry model that appeared diversified lost most diversification once positions were grouped by underlying return drivers Academic rules conflict on count - Evans & Archer (1968) says 10-15 stocks, Statman (1987) 30-40, Statman (2004) >300...

    Leo Nelissen
    •
    6/29/26
    •
    376
    Portfolio Construction
    Also mentions:
    DHRTMOODFLINTUUNP

    The Biggest Healthcare Disconnect In Decades - And The Stocks I’m Watching

    Healthcare has hit a 26-year relative low, but weakness alone does not make the sector a buy. AI-led capital flows, patent cliffs, IRA pricing pressure, and GLP-1 disruption explain much of the selloff. I prefer selective exposure: picks-and-shovels, AI-driven platforms...

    Leo Nelissen
    •
    5/25/26
    •
    459
    Healthcare Stocks, Dividend Investing, value investing
    Also mentions:
    TMOWSTLLYISRGPFE

    Government Contracts

    Gov Obligations (TTM)
    $83.26M
    Gov Obligations / Revenue
    0.2%
    Obligations YoY
    -24.8%
    Active Awards
    915
    New Awards (TTM)
    494
    Avg Remaining Term
    5.8 mo

    Top agency: Department of Justice at 26.6% of trailing twelve month obligations across 16 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    15F06726F0000364Department of JusticeFederal Bureau of Investigation$9.80MMar 13, 2026
    1333ND26PNB030039Department of CommerceNational Institute of Standards and Technology$4.49MMar 27, 2026
    75N92025P00391Department of Health and Human ServicesNational Institutes of Health$1.94MSep 22, 2025
    12639526F0606Department of AgricultureAnimal and Plant Health Inspection Service$1.50MJun 5, 2026
    36C26326N0198Department of Veterans AffairsDepartment of Veterans Affairs$1.26MOct 1, 2025
    75N98026F00135Department of Health and Human ServicesNational Institutes of Health$1.23MMay 11, 2026
    70B04C26P00000067Department of Homeland SecurityU.S. Customs and Border Protection$1.22MApr 1, 2026
    36C26226P0487Department of Veterans AffairsDepartment of Veterans Affairs$1.08MFeb 10, 2026
    75N98026F00203Department of Health and Human ServicesNational Institutes of Health$999832Jun 25, 2026
    N0010426PBJ98Department of DefenseDepartment of the Navy$899640Feb 11, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Danaher stock: TD Cowen lifts target to USD 255.00 for Danaher stock

    TD Cowen has increased its price target for Danaher (DHR) stock to $255.00 from $236.00, maintaining a Buy rating. This adjustment comes ahead of Danaher's third-quarter 2026 results, expected on October 21, 2026...

    ad-hoc-news.de•10/16/26•Neutral

    Thermo Fisher Scientific stock sits 1.07 percent below its 52-week high

    Thermo Fisher Scientific stock is trading 1.07 percent below its 52-week high of USD 704.00, with its U.S. quote at USD 696.49. Guggenheim maintains a Buy rating and a USD 740.00 price target for the company. Investors...

    ad-hoc-news.de•10/16/26•Neutral

    Philip Morris International (PM) Q3 2026 Preview: EPS Est. $2.32, Reports October 21

    Philip Morris International (PM) is expected to report modest growth for its Q3 2026 results on October 21, with analysts forecasting EPS of $2.32 on revenue of $11.38 billion. This represents a 3.6% increase in EPS...

    AlphaStreet•10/16/26•Neutral

    Thermo Fisher Scientific (TMO) Q3 2026 Preview: EPS Est. $6.40, Reports October 21

    Thermo Fisher Scientific (TMO) is set to report its Q3 2026 earnings on October 21, with analysts expecting EPS of $6.40 and revenue of $11.93 billion. These estimates represent year-over-year growth of 10.5% in EPS...

    AlphaStreet•10/16/26•Somewhat-Bullish

    JPMorgan raises target for Qiagen stock to USD 55.00

    JPMorgan has increased its target price for Qiagen (QGEN) stock from USD 50.00 to USD 55.00, maintaining an overweight rating. This decision follows Qiagen's strong Q2 2026 revenue of USD 535.04 million...

    ad-hoc-news.de•10/16/26•Neutral

    TMO Valuation and Fair Value

    P/E
    28.3x
    Forward P/E
    24.1x
    EV/EBITDA
    26.0x
    P/FCF
    34.1x
    PEG
    2.0x
    P/B
    4.7x
    See GNG's fair value

    TMO Profitability: Margins, ROIC and FCF

    Gross margin
    40.8%
    Operating margin
    18.8%
    Net margin
    15.0%
    ROIC
    7.9%
    ROE
    13.5%
    FCF margin
    15.8%
    FCF yield
    2.9%

    TMO Competitors

    CompanyTicker
    AstraZeneca PLCAZN
    Amgen IncAMGN
    Novartis AG ADRNVS
    Gilead Sciences IncGILD
    UnitedHealth Group IncorporatedUNH
    Abbott LaboratoriesABT
    Merck & Company IncMRK
    Novo Nordisk A/SNVO

    Sector: Healthcare

    TMO Analyst Ratings

    Consensus
    Buy
    Analysts
    28
    Strong Buy
    4
    Buy
    19
    Hold
    4
    Sell
    0
    Strong Sell
    1

    TMO Bull Case vs Bear Case

    Bull case

    • TMO converts 15.8% of revenue into free cash flow.
    • TMO beat EPS estimates in 100.0% of its last 8 reported quarters.
    • TMO grew quarterly revenue 10.5% year over year.

    TMO Earnings: Beat Rate and Next Report

    Beat rate
    8 of 8 quarters (100.0%)
    Average surprise
    2.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $6.40
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 2 down

    TMO Dividend

    Forward yield
    0.3%
    Payout ratio
    7.6%
    3Y DPS growth
    12.7%
    5Y DPS growth
    14.3%
    Pay months
    Jan, Apr, Jul, Oct
    TMO dividend history

    Frequently Asked Questions About TMO

    What is TMO's current dividend yield?

    Thermo Fisher Scientific Inc (TMO) has a forward dividend yield of 0.28%.

    Does TMO pay dividends?

    Yes, Thermo Fisher Scientific Inc pays dividends with a forward dividend yield of 0.28%.

    What is TMO's P/E ratio?

    Thermo Fisher Scientific Inc has a price-to-earnings (P/E) ratio of 28.25.

    What is TMO's market cap?

    Thermo Fisher Scientific Inc (TMO) has a market capitalization of $248.91B with a current stock price of $673.20.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In